Abiomed (ABMD) Tops Q3 EPS by 3c; Narrows Margin Guidance

Abiomed (NASDAQ: ABMD) reported Q3 EPS of $0.97, $0.03 better than the analyst estimate of $0.94. Revenue for the quarter came in at $200.6 million versus the consensus estimate of $195.97 million.

GUIDANCE:

As previously announced, the company increased its 2019 revenue guidance to $780 million, up from a range of $765 million to $770 million, an increase in revenue of approximately 31% from the prior year. The company is now updating its fiscal year 2019 guidance for GAAP operating margin to the range of 29% to 29.5%. This compares to the company’s prior fiscal 2019 guidance of 28% to 30%.

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Movano (MOVE) Misses Q2 EPS by 195c